Bendamustine plus rituximab for treatment of WM: patient outcomes and impact of dosing

Key Findings

• ●250 WM patients treated with BR in frontline and relapsed settings
• ●Frontline response rate (PR or better) 91.4% vs 73.9% in relapsed
• ●Major multicenter study establishing BR efficacy in WM

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works